1. Home
  2. ADVM vs NRT Comparison

ADVM vs NRT Comparison

Compare ADVM & NRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • NRT
  • Stock Information
  • Founded
  • ADVM 2006
  • NRT 1975
  • Country
  • ADVM United States
  • NRT United States
  • Employees
  • ADVM N/A
  • NRT N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • NRT Oil & Gas Production
  • Sector
  • ADVM Health Care
  • NRT Energy
  • Exchange
  • ADVM Nasdaq
  • NRT Nasdaq
  • Market Cap
  • ADVM 47.4M
  • NRT 44.0M
  • IPO Year
  • ADVM 2014
  • NRT N/A
  • Fundamental
  • Price
  • ADVM $2.39
  • NRT $5.10
  • Analyst Decision
  • ADVM Strong Buy
  • NRT
  • Analyst Count
  • ADVM 5
  • NRT 0
  • Target Price
  • ADVM $23.80
  • NRT N/A
  • AVG Volume (30 Days)
  • ADVM 338.5K
  • NRT 22.3K
  • Earning Date
  • ADVM 08-11-2025
  • NRT 05-30-2025
  • Dividend Yield
  • ADVM N/A
  • NRT 9.41%
  • EPS Growth
  • ADVM N/A
  • NRT 24.05
  • EPS
  • ADVM N/A
  • NRT 0.59
  • Revenue
  • ADVM $1,000,000.00
  • NRT $6,184,173.00
  • Revenue This Year
  • ADVM N/A
  • NRT N/A
  • Revenue Next Year
  • ADVM $18.82
  • NRT N/A
  • P/E Ratio
  • ADVM N/A
  • NRT $8.66
  • Revenue Growth
  • ADVM N/A
  • NRT 18.55
  • 52 Week Low
  • ADVM $1.78
  • NRT $3.88
  • 52 Week High
  • ADVM $10.14
  • NRT $6.90
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 44.75
  • NRT 51.31
  • Support Level
  • ADVM $2.11
  • NRT $4.88
  • Resistance Level
  • ADVM $2.60
  • NRT $5.32
  • Average True Range (ATR)
  • ADVM 0.22
  • NRT 0.16
  • MACD
  • ADVM -0.00
  • NRT -0.04
  • Stochastic Oscillator
  • ADVM 36.39
  • NRT 35.09

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

About NRT North European Oil Royality Trust

North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.

Share on Social Networks: